Since AKT signaling promotes cell survival, the ERK pathway-targeted drug-induced PHLDA1/2 downregulation and consequent AKT activation may prevent apoptosis of cancer cells and confer resistance to such anti-cancer agents. This evidence concerns the gene PHLDA1 and cancer.